Exosens SAS/ADR
No enriched coverage for $EXOSF in the last 7 days.
No SEC Form 4 filings for $EXOSF in the last 30 days.
See all $EXOSF insider activity →Exosens (EXENS) stock surged 12.1% to €60.90 after revising its 2026 outlook, raising revenue guidance to €558M-€570M from €520M-€540M and EBITDA to €186M-€192M from €168M-€178M. CEO Jerome Cerisier cited faster production ramp-up. No analyst upgrades or insider transactions were reported. The broader market was supportive, with global indices trading higher.
Exosens' subsidiary, Photonis Defense, received a $1.6B order for 1,600 BiNOD systems from the U.S. Army, marking a key milestone in Exosens' U.S. expansion. Deliveries are expected by the end of 2026, with the bulk in 2027. The order supports the BiNOD program's Low-Rate Initial Production phase, leveraging Photonis Defense's U.S. production capabilities and Exosens' technology leadership. Financial terms were not disclosed.
Exosens (EPA: EXENS) reported H1 fiscal 2026 adjusted EBIT of €71m, above the €67m forecast, up 19.2% YoY, with a 28.4% margin. Revenue was €253m, slightly below €254m consensus, but up 11.4% YoY. Q2 revenue was €130.5m. It reaffirmed FY2026 guidance: revenue €520-540m and adjusted EBITDA €168-178m, aiming for upper-end results.
Recent EXOSF coverage spans earnings and financial news.
Exosens (EXENS) stock surged 12.1% to €60.90 after revising its 2026 outlook, raising revenue guidance to €558M-€570M from €520M-€540M and EBITDA to €186M-€192M from €168M-€178M. CEO Jerome Cerisier cited faster production ramp-up. No analyst upgrades or insider transactions were reported. The broader market was supportive, with global indices trading higher.
Exosens' subsidiary, Photonis Defense, received a $1.6B order for 1,600 BiNOD systems from the U.S. Army, marking a key milestone in Exosens' U.S. expansion. Deliveries are expected by the end of 2026, with the bulk in 2027. The order supports the BiNOD program's Low-Rate Initial Production phase, leveraging Photonis Defense's U.S. production capabilities and Exosens' technology leadership. Financial terms were not disclosed.
Exosens (EPA: EXENS) reported H1 fiscal 2026 adjusted EBIT of €71m, above the €67m forecast, up 19.2% YoY, with a 28.4% margin. Revenue was €253m, slightly below €254m consensus, but up 11.4% YoY. Q2 revenue was €130.5m. It reaffirmed FY2026 guidance: revenue €520-540m and adjusted EBITDA €168-178m, aiming for upper-end results.
AlphAI scores every news story that mentions EXOSF with an AI model for sentiment and relevance, and aggregates insider trades from Exosens SAS/ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
Exosens (EXENS) stock surged 12.1% to €60.90 after revising its 2026 outlook, raising revenue guidance to €558M-€570M from €520M-€540M and EBITDA to €186M-€192M from €168M-€178M. CEO Jerome Cerisier cited faster production ramp-up. No analyst upgrades or insider transactions were reported. The broader market was supportive, with global indices trading higher.
2 min readExosens' subsidiary, Photonis Defense, received a $1.6B order for 1,600 BiNOD systems from the U.S. Army, marking a key milestone in Exosens' U.S. expansion. Deliveries are expected by the end of 2026, with the bulk in 2027. The order supports the BiNOD program's Low-Rate Initial Production phase, leveraging Photonis Defense's U.S. production capabilities and Exosens' technology leadership. Financial terms were not disclosed.
2 min readExosens (EPA: EXENS) reported H1 fiscal 2026 adjusted EBIT of €71m, above the €67m forecast, up 19.2% YoY, with a 28.4% margin. Revenue was €253m, slightly below €254m consensus, but up 11.4% YoY. Q2 revenue was €130.5m. It reaffirmed FY2026 guidance: revenue €520-540m and adjusted EBITDA €168-178m, aiming for upper-end results.
4 min read
